NR4A3 and metabolic disease: NOR1 is also considered a potential drug target for the treatment of liver fibrosis (Vacca et al., 2013), metabolic disorders associated with an imbalance of lipogenesis and glucose homeostasis (Pei et al., 2006; Myers et al., 2009; Oita et al., 2009), and osteoarthritis (Ma et al., 2020) or rheumatoid arthritis (Andreas et al., 2009).